PMID- 36361783
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20221117
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 21
DP  - 2022 Oct 27
TI  - Capability of Human Dendritic Cells Pulsed with Autologous Induced Pluripotent 
      Stem Cell Lysate to Induce Cytotoxic T Lymphocytes against HLA-A33-Matched Cancer 
      Cells.
LID - 10.3390/ijms232112992 [doi]
LID - 12992
AB  - Irradiated murine induced-pluripotent stem cells (iPSCs) elicit the antitumor 
      response in vivo. However, it is unclear whether human iPSCs would elicit 
      antitumor effects. In the present study, we investigated the capability of human 
      iPSC lysate (iPSL)-pulsed dendritic cells (DCs) (iPSL/DCs) to induce 
      cancer-responsive cytotoxic T lymphocytes (CTLs) in vitro. iPSCs and DCs were 
      induced from peripheral blood mononuclear cells isolated from a human leukocyte 
      antigen (HLA)-A33 homozygous donor. The iPSL was pulsed with immature DCs, which 
      were then stimulated to allow full maturation. The activated DCs were co-cultured 
      with autologous CTLs and their responses to SW48 colorectal carcinoma cells 
      (HLA-A32/A33), T47D breast cancer cells (HLA-A33/A33), and T98G glioblastoma 
      cells (HLA-A02/A02) were tested with enzyme-linked immunospot (ELISPOT) assays. 
      Comprehensive gene expression analysis revealed that the established iPSCs shared 
      numerous tumor-associated antigens with the SW48 and T47D cells. 
      Immunofluorescent analysis demonstrated that the fluorescent-labeled iPSL was 
      captured by the immature DCs within 2 h. iPSL/DCs induced sufficient CTL numbers 
      in 3 weeks for ELISPOT assays, which revealed that the induced CTLs responded to 
      SW48 and T47D cells. Human iPSL/DCs induced cancer-responsive CTLs on 
      HLA-A33-matched cancer cells in vitro and could be a promising universal cancer 
      vaccine for treating and preventing cancer.
FAU - Nakazawa, Tsutomu
AU  - Nakazawa T
AUID- ORCID: 0000-0003-4286-9356
AD  - Department of Research and Development, Grandsoul Research Institute for 
      Immunology, Matsui 8-1, Utano, Uda 633-2221, Nara, Japan.
AD  - Clinic Grandsoul Nara, Matsui 8-1, Utano, Uda 633-2221, Nara, Japan.
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Maeoka, Ryosuke
AU  - Maeoka R
AUID- ORCID: 0000-0003-1441-838X
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Morimoto, Takayuki
AU  - Morimoto T
AUID- ORCID: 0000-0002-9974-3538
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Matsuda, Ryosuke
AU  - Matsuda R
AUID- ORCID: 0000-0002-0307-3657
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Nakamura, Mitsutoshi
AU  - Nakamura M
AUID- ORCID: 0000-0002-7920-2048
AD  - Clinic Grandsoul Nara, Matsui 8-1, Utano, Uda 633-2221, Nara, Japan.
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Nishimura, Fumihiko
AU  - Nishimura F
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Yamada, Shuichi
AU  - Yamada S
AUID- ORCID: 0000-0002-7278-3978
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Nakagawa, Ichiro
AU  - Nakagawa I
AUID- ORCID: 0000-0002-1340-3293
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Park, Young-Soo
AU  - Park YS
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Nakase, Hiroyuki
AU  - Nakase H
AUID- ORCID: 0000-0002-2726-5960
AD  - Department of Neurosurgery, Nara Medical University, Kashihara 634-8522, Nara, 
      Japan.
FAU - Tsujimura, Takahiro
AU  - Tsujimura T
AD  - Department of Research and Development, Grandsoul Research Institute for 
      Immunology, Matsui 8-1, Utano, Uda 633-2221, Nara, Japan.
AD  - Clinic Grandsoul Nara, Matsui 8-1, Utano, Uda 633-2221, Nara, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221027
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (HLA-A*33 antigen)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Humans
MH  - Mice
MH  - Animals
MH  - T-Lymphocytes, Cytotoxic
MH  - *Induced Pluripotent Stem Cells
MH  - Leukocytes, Mononuclear/metabolism
MH  - Dendritic Cells
MH  - Histocompatibility Antigens Class II/metabolism
MH  - HLA Antigens/metabolism
MH  - *Neoplasms/metabolism
PMC - PMC9654950
OTO - NOTNLM
OT  - cancer immunotherapy
OT  - cancer vaccine
OT  - cytotoxic lymphocyte (CTL)
OT  - dendritic cell (DC)
OT  - induced pluripotent stem cell (iPSC)
COIS- T.N. and M.N. are registered as research fellows at Nara Medical University.
EDAT- 2022/11/12 06:00
MHDA- 2022/11/15 06:00
PMCR- 2022/10/27
CRDT- 2022/11/11 01:25
PHST- 2022/10/02 00:00 [received]
PHST- 2022/10/25 00:00 [revised]
PHST- 2022/10/25 00:00 [accepted]
PHST- 2022/11/11 01:25 [entrez]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/10/27 00:00 [pmc-release]
AID - ijms232112992 [pii]
AID - ijms-23-12992 [pii]
AID - 10.3390/ijms232112992 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Oct 27;23(21):12992. doi: 10.3390/ijms232112992.